Bevacizumab (Avastin)

Size: px
Start display at page:

Download "Bevacizumab (Avastin)"

Transcription

1 Bevacizumab (Avastin) Policy Number: Original Effective Date: MM /14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service: Home I. Description Bevacizumab (Avastin) is FDA approved for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-fluorouracil-based chemotherapy. Bevacizumab is FDA approved for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel. Bevacizumab is FDA approved for the treatment of glioblastoma with progressive disease following prior therapy as a single agent. Bevacizumab is FDA approved for the treatment of metastatic renal cell carcinoma in combination with interferon alfa. The FDA has withdrawn its approval for metastatic HER2-negative breast cancer however; NCCN continues to recommend (2A) the use of bevacizumab in combination with paclitaxel for recurrent or metastatic disease that is: hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative with visceral crisis HER2-negative and either hormone receptor-negative or hormone receptor-positive and endocrine therapy refractory progressive with no clinical benefit after three consecutive endocrine therapy regimens or with symptomatic visceral disease Bevacizumab is administered by intravenous infusion for cancer indications or intravitreally for macular degeneration. It is a monoclonal antibody that binds vascular endothelial growth factor (VEGF) and prevents interaction of VEGF to its receptors thus preventing the stimulation of new blood vessels.

2 Bevacizumab (Avastin) 2 II. Criteria/Guidelines A. Bevacizumab is covered (subject to Limitation/Exclusions and Administrative Guidelines) when recommended by an oncologist and the following criteria are met: 1. For treatment of metastatic cancer of the colon and/or rectum when used as first or second line treatment in combination with other chemotherapeutic agent(s). 2. For treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer: a. Bevacizumab must be used as first line treatment. b. Bevacizumab must be used in combination with carboplatin (Paraplatin) and paclitaxel (Taxol). c. Bevacizumab may be used as monotherapy after four to six cycles in combination with paclitaxel and carboplatin until there is disease progression or unacceptable toxicity. 3. For treatment of HER2 negative metastatic breast cancer in combination with paclitaxel for recurrent or metastatic disease that is: a. Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative with visceral crisis. b. HER2-negative and either hormone receptor-negative or hormone receptor-positive and endocrine therapy refractory. c. Progressive with no clinical benefit after three consecutive endocrine therapy regimens or with symptomatic visceral disease. 4. For treatment of kidney cancer, bevacizumab must be used in combination with interferon alfa. 5. For treatment of ovarian cancer, HMSA follows NCCN level 1 or 2A and/or DrugDex level I or IIa recommendations. 6. For glioblastoma, bevacizumab must be used in progressive disease following prior therapy as a single agent. B. For all indications, HMSA follows NCCN level 1 or 2A and/or DrugDex level I or IIa recommendations. C. Patients with cancer whose therapy has been interrupted due to surgery or other medical complications not related to bevacizumab are eligible for continued therapy if the above criteria are met. D. Continuation of therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) when the initial therapy has been approved and the patient shows no progression of disease while on bevacizumab, except for colorectal cancer, HMSA follows NCCN level 1 or 2A and/or DrugDex level I or IIa recommendations. E. Bevacizumab is covered for the following ophthalmic indications: 1. Treatment of neovascular (wet) age-related macular degeneration. 2. Choroid neovascular membrane (CNVM) or choroidal neovascularization (CNV) secondary to myopia. 3. Macular edema following retinal vein occlusion. 4. Diabetic. III. Limitations/Exclusions

3 Bevacizumab (Avastin) 3 For oncology indications, with the exception of colorectal cancer, bevacizumab is not covered for a patient who has had progression of disease while on bevacizumab. For colorectal cancer, HMSA follows NCCN level 1 or 2A and/or DrugDex level I or IIa recommendations. IV. Administrative Guidelines A. Precertification is required for the initial three months of therapy for the treatment of cancer. To precertify, please complete HMSA's Drug Review Request and mail or fax the form as indicated. The following documentation must be submitted: 1. Clinical notes that include the history of previous treatments 2. Current oncology notes 3. Pathology reports 4. Imaging studies 5. CEA for colorectal cancer B. Precertification is required for continuation of therapy for up to an additional three months. The following documentation from the medical record must be submitted: 1. Current oncology notes documenting the patient's response to treatment and that show no progression of disease, with the exception of colorectal cancer. 2. Objective findings demonstrating no progression of disease (i.e., CEA and/or imaging) when compared to previous studies, with the exception of colorectal cancer. C. Precertification is not required for bevacizumab when it is prescribed for ophthalmic indications listed above in II.E. and when the following codes are used to reflect the covered ophthalmic indications. All other indications require precertification. Precertification is required for the following: HCPCS Code J9035 Description Injection, bevacizumab, 10 mg Precertification is not required when bevacizumab is prescribed for ophthalmic indications; use HCPCS code J3590 with the following ICD-9 codes for ophthalmic indications: ICD-9 code Description Exudative senile macular degeneration Progressive high (degenerative) myopia, when billed with: Retinal neovascularization NOS Central retinal vein occlusion

4 Bevacizumab (Avastin) Venous tributary (branch) occlusion Diabetic ICD-10 codes are provided for your information. These will not become effective until 10/1/2014. ICD9 Code Description H35.32 Exudative age-related macular degeneration H44.20 Degenerative myopia, unspecified eye H44.21 Degenerative myopia, right eye H44.22 Degenerative myopia, left eye H44.23 Degenerative myopia, bilateral when billed with: H Retinal neovascularization, unspecified, right eye H Retinal neovascularization, unspecified, left eye H Retinal neovascularization, unspecified, bilateral H Retinal neovascularization, unspecified, unspecified eye H Central retinal vein occlusion, right eye H Central retinal vein occlusion, left eye H Central retinal vein occlusion, bilateral H Central retinal vein occlusion, unspecified eye when billed with H Tributary (branch) retinal vein occlusion, right eye H Tributary (branch) retinal vein occlusion, left eye H Tributary (branch) retinal vein occlusion, bilateral H Tributary (branch) retinal vein occlusion, unspecified eye E Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with E Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with

5 Bevacizumab (Avastin) 5 E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with E Type 1 diabetes mellitus with unspecified diabetic retinopathy with E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with E Type 1 diabetes mellitus with proliferative diabetic retinopathy with E Type 2 diabetes mellitus with unspecified diabetic retinopathy with E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with E Type 2 diabetes mellitus with proliferative diabetic retinopathy with E Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with E Other specified diabetes mellitus with proliferative diabetic retinopathy with V. Important Reminder

6 Bevacizumab (Avastin) 6 The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. VI. References 1. Avastin prescribing information. Genentech, Inc., 3/ Burger RA, Brady MF, Bookman MA. Et al. Incorporation of Bevacizumab in the treatment of ovarian cancer. N Engl J Med 2011; 365: DrugDex Evaluations. Bevacizumab Clinical Applications. Last modified: September 24, Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Eng J Med. 357; 26, December 27, National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast cancer. Version National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Colon cancer. Version National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Kidney cancer. Version National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Central nervous system cancers. Version National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non small cell lung cancer. Version National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355; 24, December 14, 2006.

7 Bevacizumab (Avastin) Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Executive Summary Health Technology Assessment 2010; Volume 14: Number NCCN Drugs and Biologics Compendium. Bevacizumab CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med May 19; 364(20): Epub 2011 Apr Zhu J, Sharma DB, Gray SW, et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non small cell lung cancer. JAMA, April 18, : 15;

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127 Clinical Policy: (Avastin) Reference Number: ERX.SPMN.127 Effective Date: 03/14 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors Ophthalmologic Policy UnitedHealthcare Commercial Drug Policy Vascular Endothelial Growth Factor (VEGF) Inhibitors Policy Number: 2016D0042H Effective Date: October 1, 2016 Table of Contents Page INSTRUCTIONS

More information

Perjeta (pertuzumab)

Perjeta (pertuzumab) Perjeta (pertuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201809/16/2018 POLICY A. INDICATIONS The indications

More information

OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS

OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS UnitedHealthcare Commercial Medical Benefit Drug Policy OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS Policy Number: PHA020 Effective Date: September 1, 2018 Table of Contents

More information

Avastin (bevacizumab)

Avastin (bevacizumab) Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.04 Subject: Avastin Page: 1 of 8 Last Review Date: December 3, 2015 Avastin Description Avastin (bevacizumab)

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)

More information

Cyramza (ramucirumab)

Cyramza (ramucirumab) Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

Torisel (temsirolimus)

Torisel (temsirolimus) Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/1/2017 POLICY A. INDICATIONS The indications below

More information

Bortezomib (Velcade)

Bortezomib (Velcade) Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)

More information

Erythropoiesis Stimulating Agents (ESA)

Erythropoiesis Stimulating Agents (ESA) Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription

More information

Clinical Policy: Bevacizumab (Avastin) Reference Number: CP.PHAR.93

Clinical Policy: Bevacizumab (Avastin) Reference Number: CP.PHAR.93 Clinical Policy: (Avastin) Reference Number: CP.PHAR.93 Effective Date: 12/11 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications

More information

Torisel (temsirolimus)

Torisel (temsirolimus) Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/01/2017TBD03/01/2017 POLICY A. INDICATIONS The indications

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below

More information

Keytruda (pembrolizumab)

Keytruda (pembrolizumab) Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The

More information

Gazyva (obinutuzumab)

Gazyva (obinutuzumab) Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications

More information

Somatuline Depot (lanreotide)

Somatuline Depot (lanreotide) Somatuline Depot (lanreotide) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications

More information

Low-Molecular-Weight Heparin

Low-Molecular-Weight Heparin Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Bevacizumab (Avastin, Mvasi) Reference Number: CP.PHAR.93 Effective Date: 12.01.11 Last Review Date: 11.18 Line of Business: Commercial, HIM*, Medicaid Coding Implications Revision Log

More information

Limitation(s) of use: Avastin is not indicated for adjuvant treatment of colon cancer.

Limitation(s) of use: Avastin is not indicated for adjuvant treatment of colon cancer. Clinical Policy: (Avastin) Reference Number: CP.PHAR.93 Effective Date: 12.01.11 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Coding Implications Revision

More information

Negative Pressure Wound Therapy (NPWT)

Negative Pressure Wound Therapy (NPWT) Negative Pressure Wound Therapy (NPWT) Policy Number: Original Effective Date: MM.01.005 11/19/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 01/01/2015 Section: DME Place(s) of Service:

More information

Where Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines?

Where Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines? Introduction Additionally, other anti-angiogenic drugs, including sorafenib, sunitinib, axitinib, pazopanib, vandetanib, The development and subsequent use of drugs for treating cancer cabozantinib, and

More information

Avastin Sample Coding

Avastin Sample Coding First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant

More information

Insulin Pumps - External

Insulin Pumps - External Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of

More information

Bariatric Surgery MM /11/2001. HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient; Inpatient

Bariatric Surgery MM /11/2001. HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient; Inpatient Bariatric Surgery Policy Number: Original Effective Date: MM.06.003 09/11/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient;

More information

Growth Hormone Therapy

Growth Hormone Therapy Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)

More information

Intensity Modulated Radiation Therapy (IMRT)

Intensity Modulated Radiation Therapy (IMRT) Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 03/01/2015 Section: Radiology

More information

Intensity Modulated Radiation Therapy (IMRT)

Intensity Modulated Radiation Therapy (IMRT) Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO 06/24/2011 Section: Radiology Place(s) of

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lucentis) Reference Number: CP.PHAR.186 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the

More information

Pulmonary Hypertension Drugs

Pulmonary Hypertension Drugs Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/22/2015 Section: Prescription Drugs

More information

Eylea (aflibercept) Document Number: IC-0026

Eylea (aflibercept) Document Number: IC-0026 Eylea (aflibercept) Document Number: IC-0026 Last Review Date: 3/1/2018 Date of Origin: 02/07/2013 Dates Reviewed: 03/07/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 04/2015,

More information

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Policy Number: Original Effective Date: MM.12.022 01/01/2016 Line(s) of Business: Current Effective Date: HMO; PPO; Fed 87; FEP;

More information

Bevacizumab 7.5mg/kg Therapy 21 days

Bevacizumab 7.5mg/kg Therapy 21 days INDICATIONS FOR USE: Bevacizumab 7.5mg/kg Therapy 21 days INDICATION ICD10 Regimen Code *Reimbursement status In combination with fluoropyrimidine-based chemotherapy for C18 00214a Hospital treatment of

More information

Home Total Parenteral Nutrition for Adults

Home Total Parenteral Nutrition for Adults Home Total Parenteral Nutrition for Adults Policy Number: Original Effective Date: MM.08.007 05/21/1999 Line(s) of Business: Current Effective Date: PPO, HMO, QUEST Integration 05/27/2016 Section: Home

More information

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119 Clinical Policy: (Cyramza) Reference Number: CP.PHAR.119 Effective Date: 05/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Posterior Tibial Nerve Stimulation

Posterior Tibial Nerve Stimulation Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)

More information

Clinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94

Clinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94 Clinical Policy: (Perjeta) Reference Number: ERX.SPMN.94 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Eylea) Reference Number: CP.PHAR.184 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at the

More information

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Policy Number: Original Effective Date: MM.12.022 01/01/2016 Line(s) of Business: Current Effective Date: HMO; PPO; Fed 87; FEP;

More information

Lung-Volume Reduction Surgery ARCHIVED

Lung-Volume Reduction Surgery ARCHIVED Lung-Volume Reduction Surgery ARCHIVED Policy Number: Original Effective Date: MM.06.008 04/15/2005 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST 03/22/2013 Section: Surgery Place(s) of

More information

Erbitux. Erbitux (cetuximab) Description

Erbitux. Erbitux (cetuximab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)

More information

Oxygen and Oxygen Equipment

Oxygen and Oxygen Equipment Oxygen and Oxygen Equipment Policy Number: Original Effective Date: MM.01.008 12/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013 Section: DME Place(s) of Service: Home I.

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017

More information

Avastin (bevacizumab) (Intravenous/Intravitreal)

Avastin (bevacizumab) (Intravenous/Intravitreal) (Intravenous/Intravitreal) Date of Origin: 10/17/08 Dates Reviewed: 6/17/2009, 12/22/2009, 03/2010, 06/2010, 09/21/2010, 12/2010, 2/15/2011, 03/2011, 06/2011, 09/2011, 12/2011, 03/2011, 6/19/2012, 09/06/2012,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Abraxane) Reference Number: CP.PHAR.176 Effective Date: 07.01.15 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of

More information

Date approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy

Date approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy Integrated Healthcare Services and Criteria Document: Reference #: PC/V001 Page: 1 of 9 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services,

More information

Incontinence Supplies

Incontinence Supplies Incontinence Supplies Policy Number: Original Effective Date: MM.12.020 07/01/2015 Lines of Business: Current Effective Date: QUEST Integration 09/28/2018 Section: Other/Miscellaneous Place(s) of Service:

More information

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Cyramza) Reference Number: CP.HNMC.09 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2013 Section:

More information

Prophylactic Mastectomy

Prophylactic Mastectomy Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.

More information

Bevacizumab 10mg/kg 14 days

Bevacizumab 10mg/kg 14 days INDICATIONS FOR USE: Bevacizumab 10mg/kg 14 days Regimen Code 00212a *Reimbursement status Hospital INDICATION ICD10 In combination with fluoropyrimidine-based chemotherapy C18 for treatment of adult patients

More information

Oxygen and Oxygen Equipment

Oxygen and Oxygen Equipment Oxygen and Oxygen Equipment Policy Number: Original Effective Date: MM.01.008 12/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: DME Place(s) of Service:

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015

More information

Micro-Invasive Glaucoma Surgery (Aqueous Stents)

Micro-Invasive Glaucoma Surgery (Aqueous Stents) Micro-Invasive Glaucoma Surgery (Aqueous Stents) Policy Number: Original Effective Date: MM.06.029 02/01/2019 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2019 Section:

More information

Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office

Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service:

More information

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Verteporfin (Visudyne) Reference Number: CP.PHAR.187 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important

More information

NCCP Chemotherapy Regimen. Bevacizumab 15mg/kg Therapy 21 days

NCCP Chemotherapy Regimen. Bevacizumab 15mg/kg Therapy 21 days Bevacizumab 15mg/kg Therapy 21 days INDICATIONS FOR USE: INDICATION ICD10 Regimen Code In combination with carboplatin and paclitaxel is indicated for the frontline 00215a treatment of adult patients with

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Ophthalmic VEGF Inhibitors Page: 1 of 5 Last Review Date: September 20, 2018 Ophthalmic VEGF Inhibitors

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including

More information

Clinical Policy: Lenvatinib (Lenvima) Reference Number: CP.CPA.251 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Lenvatinib (Lenvima) Reference Number: CP.CPA.251 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Lenvima) Reference Number: CP.CPA.251 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2015

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Trastuzumab (Herceptin), Trastuzumab-dkst (Ogivri) Reference Number: CP.PHAR.228 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Coding Implications

More information

Subject: Bevacizumab (Avastin ) Injection

Subject: Bevacizumab (Avastin ) Injection 09-J0000-66 Original Effective Date: 11/15/06 Reviewed: 06/13/18 Revised: 08/15/18 Subject: Bevacizumab (Avastin ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Kyphoplasty and Vertebroplasty

Kyphoplasty and Vertebroplasty Kyphoplasty and Vertebroplasty Policy Number: Original Effective Date: MM.06.007 01/11/2005 Line(s) of Business: Current Effective Date: HMO; PPO 02/01/2012 Section: Surgery Place(s) of Service: Inpatient;

More information

Intravitreal Avastin (Bevacizumab)

Intravitreal Avastin (Bevacizumab) Intravitreal Avastin (Bevacizumab) Date of Origin: 10/18/2018 Last Review Date: 10/18/2018 Effective Date: 10/18/2018 Dates Reviewed: 10/2018 Developed By: Medical Criteria Committee I. Length of Authorization

More information

Polysomnography and Sleep Studies

Polysomnography and Sleep Studies Polysomnography and Sleep Studies Policy Number: Original Effective Date: MM.02.016 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2014 Section: Medicine Place(s)

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved

More information

Remicade (Infliximab)

Remicade (Infliximab) Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)

More information

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Policy Number: Original Effective Date: MM.01.009 11/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Residential Treatment (RTC)

Residential Treatment (RTC) An Independent Licensee of the Blue Cross and Blue Shield Association Residential Treatment (RTC) BEACON HEALTH STRATEGIES, LLC ORIGINAL EFFECTIVE DATE HAWAII LEVEL OF CARE CRITERIA 2013 CURRENT EFFECTIVE

More information

Clinical Policy: Erlotinib (Tarceva) Reference Number: CP.PHAR74 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

Clinical Policy: Erlotinib (Tarceva) Reference Number: CP.PHAR74 Effective Date: Last Review Date: Line of Business: Oregon Health Plan Clinical Policy: (Tarceva) Reference Number: CP.PHAR74 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Subject: Axitinib (Inlyta ) Tablets

Subject: Axitinib (Inlyta ) Tablets 09-J1000-67 Original Effective Date: 05/15/12 Reviewed: 12/12/18 Revised: 01/15/19 Subject: Axitinib (Inlyta ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Extracorporeal Membrane Oxygenation (ECMO)

Extracorporeal Membrane Oxygenation (ECMO) Extracorporeal Membrane Oxygenation (ECMO) Policy Number: Original Effective Date: MM.12.006 05/16/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/01/2014 Section: Other/Miscellaneous

More information

Name of Policy: Panitumumab, Vectibix

Name of Policy: Panitumumab, Vectibix Name of Policy: Panitumumab, Vectibix Policy #: 369 Latest Review Date: June 2014 Category: Pharmacology Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross

More information

Inpatient Mental Health

Inpatient Mental Health Inpatient Mental Health BEACON HEALTH STRATEGIES, LLC ORIGINAL EFFECTIVE DATE HAWAII LEVEL OF CARE CRITERIA 2013 CURRENT EFFECTIVE DATE 2016 I. Description Acute Inpatient Psychiatric Services are the

More information

Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service: Home; Office

Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service: Home; Office Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service:

More information

NEXAVAR (sorafenib tosylate) oral tablet

NEXAVAR (sorafenib tosylate) oral tablet NEXAVAR (sorafenib tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Treatment of Varicose Veins

Treatment of Varicose Veins Treatment of Varicose Veins Policy Number: Original Effective Date: MM.06.016 04/15/2005 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration 09/28/2018 Section: Surgery Place(s) of

More information

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Policy Number: Original Effective Date: MM.01.009 11/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;

More information

Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Alimta) Reference Number: CP.PHAR.368 Effective Date: 10.31.17 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous) Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240

More information